A pilot study on the effect of apomorphine on visual perception in patients with Parkinson's disease and visual hallucinations

Phase 4

Completed

• Conditions: hypokinetic rigid syndrome; Parkinson's disease; 10028037

• Registration Number: NL-OMON31583
• Lead Sponsor: niversitair Medisch Centrum Groningen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 13 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 10

Inclusion Criteria

1. Diagnosed Parkinson*s Disease according to the UK Brain Bank Criteria
2. Al least weekly hallucinations during the past month
3. MMSE >24
4. FAB>=12
5. Patient must be able to understand the procedure
6. Medication must be stable for at least a month

Exclusion Criteria

1. Visual problems (cataract, macula degeneration, severe retinal patholgy, visus<.5)
2. Patients with cerebral electrodes for deep brain stimulation
3. Presence of other neurological or psychiatric affections
4. Unstable internal disease
5. Patients who already use apomorphine

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The change in prestation on the VOSP related to the presence or absence of the<br /><br>apomorphine infusion.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>1. Lower order visual perception tests consisting of Mars Letter Contrast<br /><br>Sensitivity Test, Visual field measurement, Primary vision measurement, Color<br /><br>differentiation, Visual overview and perceptual speed (TAVTMB).<br /><br>2. Cognitive and attentional tests consisting of reactiontime (Schuhfried S7),<br /><br>Frontal Lobe assessment Battery (FAB) and the SCOPA-Cog<br /><br>3. Motor function test consisting of the SPES/ SCOPA. </p><br>